MTD vs. NVO: Mettler-Toledo vs. Novo Nordisk Stock Comparison

Company Profile

Mettler-Toledo (MTD) and Novo Nordisk (NVO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MTD is classified in Life Sciences Tools & Services while NVO is classified in Pharmaceuticals.

Mettler-Toledo (MTD) trades as ordinary local shares, while Novo Nordisk (NVO) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Novo Nordisk (NVO) is heavily traded at around 12.11M shares per day, whereas Mettler-Toledo (MTD) sees a more moderate 197.80K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Novo Nordisk (NVO) earns 58.38% on shareholders’ equity, ranked against its industry; Mettler-Toledo (MTD) has no ROE this period.

Both Mettler-Toledo (MTD) at 22.25% and Novo Nordisk (NVO) at 33.92% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Mettler-Toledo (MTD) at 28.70% and Novo Nordisk (NVO) at 40.05% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Mettler-Toledo (MTD) at 3.98% and Novo Nordisk (NVO) at 6.43% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Mettler-Toledo (MTD) at 3.88% and Novo Nordisk (NVO) at 1.77% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

Both Mettler-Toledo (MTD) at 1.10 and Novo Nordisk (NVO) at 0.85 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Novo Nordisk (NVO) at 0.62 is near its industry mid-range for debt-to-equity ratio, while Mettler-Toledo (MTD) at 26.06 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Mettler-Toledo (MTD) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a yield of 29.03%, ranking against industry peers normally.

Mettler-Toledo (MTD) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a payout of 45.36%, ranking against industry peers normally.

Dividend Metrics

Valuation

Novo Nordisk (NVO) at 10.18 sits in the cheaper P/E ratio quartile, while Mettler-Toledo (MTD) at 37.38 is closer to its industry’s usual earnings multiple — a discount for NVO, though growth and earnings durability still matter.

Novo Nordisk (NVO) at 0.53 sits in the cheaper P/S ratio quartile while Mettler-Toledo (MTD) at 8.16 prices around its industry’s middle — NVO costs less per dollar of sales, though read it alongside growth and margins.

Novo Nordisk (NVO) at 5.43 sits near its industry’s typical P/B ratio, while Mettler-Toledo (MTD) at 442.71 prices above its benchmark range — MTD looks rich relative to book.

Valuation Metrics